372 related articles for article (PubMed ID: 12230859)
1. Patent immorality?
Bloche MG; Jungman ER
Am J Bioeth; 2002; 2(3):48-9. PubMed ID: 12230859
[No Abstract] [Full Text] [Related]
2. Not taking, just borrowing: government use of patented drugs.
Ossorio PN
Am J Bioeth; 2002; 2(3):51-2. PubMed ID: 12230861
[No Abstract] [Full Text] [Related]
3. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
Resnik DB; DeVille KA
Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
[No Abstract] [Full Text] [Related]
4. It is not unethical, though it is often unwise, to override patents.
Leventer H
Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860
[No Abstract] [Full Text] [Related]
5. Compulsory licensure: the case of Cipro and beyond.
Chakrabarty AM
Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
[No Abstract] [Full Text] [Related]
6. Who are the guardians guarding?
Trachtman H
Am J Bioeth; 2002; 2(3):46-8. PubMed ID: 12230858
[No Abstract] [Full Text] [Related]
7. The Cipro patent and bioterrorism.
Kaye KS; Kaye D
Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
[No Abstract] [Full Text] [Related]
8. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.
Viana JM
Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298
[No Abstract] [Full Text] [Related]
9. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
10. Patents: the public interest versus the private privilege.
Parsi KP; Egan EA
Am J Bioeth; 2002; 2(3):45-6. PubMed ID: 12230857
[No Abstract] [Full Text] [Related]
11. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
Schuklenk U
Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
[No Abstract] [Full Text] [Related]
12. International patent protection for HIV-related therapies: patent attorney's perspective.
Pavento LC; Greene JL; McDonald JK
Emory Int Law Rev; 2003; 17(2):919-31. PubMed ID: 15199935
[No Abstract] [Full Text] [Related]
13. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
14. Balancing access to pharmaceuticals with patent rights.
Nicol D
Monash Bioeth Rev; 2003 Apr; 22(2):50-62. PubMed ID: 15069957
[TBL] [Abstract][Full Text] [Related]
15. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
16. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
17. Essential AIDS medications in India.
Thomas J
Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
[No Abstract] [Full Text] [Related]
18. Intellectual property and pharmaceutical drugs: an ethical analysis.
De George RT
Bus Ethics Q; 2005 Oct; 15(4):549-75. PubMed ID: 16358442
[TBL] [Abstract][Full Text] [Related]
19. Are rich nations up for drug reform?
Check E
Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
[No Abstract] [Full Text] [Related]
20. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]